Acquisition, Equity-Method Investment and Licensing Arrangements - Schedule of Equity-Method Investment (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 27, 2020	Jun. 30, 2020	Sep. 29, 2019	Sep. 27, 2020	Jun. 30, 2020	Sep. 29, 2019	Jun. 28, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Current assets	$ 47,739			$ 47,739				$ 32,803
Total assets	178,983			178,983				167,489
Current liabilities	34,154			34,154				37,304
Total liabilities	113,487			113,487				104,042
Equity attributable to shareholders	65,259			65,259				63,143
Equity attributable to noncontrolling interests	236			236				303
Total equity	65,495		$ 65,396	65,495		$ 65,396	$ 64,564	$ 63,447	$ 59,924	$ 63,758
Income from continuing operations	2,202		7,680	9,046		16,625
Net income	2,202		7,684	9,046		16,628
Income attributable to shareholders	$ 2,194		$ 7,680	$ 9,022		$ 16,609
GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Current assets		$ 7,136			$ 7,136
Noncurrent assets		37,108			37,108
Total assets		44,244			44,244
Current liabilities		4,992			4,992
Noncurrent liabilities		5,195			5,195
Total liabilities		10,187			10,187
Equity attributable to shareholders		33,919			33,919
Equity attributable to noncontrolling interests		138			138
Total equity		34,057			34,057
Net sales		2,927			9,618
Cost of sales		(1,061)			(4,266)
Gross profit		1,866			5,352
Income from continuing operations		524			995
Net income		524			995
Income attributable to shareholders		$ 518			$ 959